Enhanced antithrombotic effects with the combination of rivaroxaban - a novel, oral, direct factor Xa inhibitor and clopiclogrel, in animal models

被引：0
|
作者：
Perzborn, E. [1 ]
Fischer, E. [1 ]
Lange, U. [1 ]
机构：
[1] Bayer HealthCare, Pharma R&D Discovery Res, Wuppertal, Germany
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
220
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [21] A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban
    Hosny, Noha M.
    MICROCHEMICAL JOURNAL, 2020, 159
  • [22] Rivaroxaban, an Oral, Direct Factor Xa Inhibitor: A New Option for Thromboprophylaxis
    Kwong, Louis M.
    ORTHOPEDICS, 2012, 35 (06) : E932 - E938
  • [23] Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor
    Perzborn, E.
    Hardwardt, M.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 380
  • [24] Rivaroxaban: A New Oral Factor Xa Inhibitor
    Perzborn, Elisabeth
    Roehrig, Susanne
    Straub, Alexander
    Kubitza, Dagmar
    Mueck, Wolfgang
    Laux, Volker
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (03) : 376 - U24
  • [25] Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor
    Kubitza, Dagmar
    Becka, Michael
    Mueck, Wolfgang
    Halabi, Atef
    Maatouk, Haidar
    Klause, Norbert
    Lufft, Volkmar
    Wand, Dominic D.
    Philipp, Thomas
    Bruck, Heike
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) : 703 - 712
  • [26] Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor
    Samama, Meyer Michel
    Martinoli, Jean-Luc
    LeFlem, Lena
    Guinet, Celine
    Plu-Bureau, Genevieve
    Depasse, Francois
    Perzborn, Elisabeth
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) : 815 - 825
  • [27] Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor
    Turpie, Alexander G. G.
    Kreutz, Reinhold
    Llau, Juan
    Norrving, Bo
    Haas, Sylvia
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (05) : 876 - 886
  • [28] Co-administration of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and clopidogrel in healthy subjects
    Kubitza, D.
    Becka, M.
    Mueck, W.
    Zuehlsdorf, M.
    EUROPEAN HEART JOURNAL, 2007, 28 : 189 - 189
  • [29] Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models
    Funatsu, Toshiyuki
    Yamashita, Atsushi
    Kaku, Seiji
    Iwatsuki, Yoshiyuki
    Asada, Yujiro
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (05) : 896 - 902
  • [30] RIVAROXABAN, A DIRECT FACTOR XA INHIBITOR: A DRUG UPDATE
    Shyamasakhi, P. D.
    Sania, K. M.
    Meena, N. D.
    Bikram, T.
    Tarinita, L.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2015, 6 (08): : 3186 - 3191
12345